Medical technology company Monivent is carrying out a directed issue of units of approximately SEK 11.5 million, conditional upon approval at the annual general meeting on June 9, while major shareholder Chalmers Ventures is proposing a set-off issue of approximately SEK 9.8 million to convert bridge loans into shares. "We are at a critical stage where clinical needs, regulatory progress and commercial readiness converge. With MDR approval and FDA approval as the key remaining milestones, we are approaching a phase where our global distribution agreement with Dräger can be fully activated and scaled up. This provides access to established sales channels and accelerates our transition from validation to commercial growth. The increasing demand for safer, data-driven neonatal care creates strong tailwinds for the implementation of the company’s products," CEO Maria Lindqvist says in a comment.She continues. "At the same time, the company has for a period been in a challenging financial situation, which has required extensive and at times difficult discussions about possible ways forward. Against that backdrop, it is a great relief that we have now succeeded in agreeing on a transaction that secures continued operations and creates the conditions to realize the significant potential that exists in the business. The transaction makes it possible for us to move forward with full focus on execution and is assessed to secure value for all shareholders in the long term." In connection with the issue, warrants of series TO3 will also be issued. In total, the company can be provided with up to approximately SEK 27 million including full exercise of warrants of series TO3.The subscription price has been set at SEK 0.26 per unit, corresponding to SEK 0.13 per share, which means a discount of approximately 15 percent to the VWAP during the period April 30–May 5. The directed issue comprises 44 million units and is directed to 22 external investors as well as existing owners, including Kompany 42 ApS and Chairman of the Board John Haurum. The set-off issue comprises 37.6 million units and pertains to the offsetting of loans and accrued interest.The company states that the capital will finance regulatory processes for MDR and FDA approvals, market launch with Dräger and operations until positive cash flow, which is expected during the second half of 2028. The medical technology company expects to submit a 510(k) application during the first half of this year. During the second half, MDR approval and launch in Europe together with Dräger are expected. The company further assesses that FDA approval and launch in the US with Dräger can take place during the first half of next year. The total dilution amounts to approximately 66.6 percent before full exercise of the warrants. Upon full exercise of TO3, an additional approximately SEK 15.5 million can be provided to the company.